ConformanceX addresses a proven, widespread and hugely costly need, and offers investors the potential for strong returns.
Here’s yet another example of a drug launch failure:
A top ten pharma company was due to launch a new heart drug.
A range of launch teams were assembled, from medical to marketing, and a date was set.
But at the last minute, it was realised a key data point needed for the launch had been missed.
That required the rerunning of the final study, with damaging results for the company:
- - postponement of launch by one year
- - a cost estimated at $20 million
- - and that’s just one example among hundreds, with the number growing every month.
The power of our ability to greatly reduce such damaging losses means:
Within five years we anticipate annual revenues in excess of $30 million.